Nipocalimab
- Generic Name
- Nipocalimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2211985-36-1
- Unique Ingredient Identifier
- 87M90CV8NC
- Background
Nipocalimab is under investigation in clinical trial NCT04119050 (Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of JNJ-80202135 in Healthy Chinese Adult Participants
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT05151692
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 53
- Registration Number
- NCT04991753
- Locations
- 🇵🇱
Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland
🇵🇱Centrum Medyczne AMED Targowek, Warszawa, Poland
🇪🇸Hosp Univ A Coruna, A Coruna, Spain
A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT04973566
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
- Conditions
- Interventions
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 163
- Registration Number
- NCT04968912
- Locations
- 🇺🇸
St. Paul Rheumatology P A, Eagan, Minnesota, United States
🇪🇸Hosp Reina Sofia, Córdoba, Spain
🇪🇸Hosp Univ A Coruna, La Coruña, Spain
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 198
- Registration Number
- NCT04951622
- Locations
- 🇺🇸
Neuromuscular Research Center and Clinic, Paradise Valley, Arizona, United States
🇺🇸HonorHealth Neurology, Scottsdale, Arizona, United States
🇺🇸University of Southern California, Los Angeles, California, United States
A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 228
- Registration Number
- NCT04882878
- Locations
- 🇺🇦
Medbud-Clinic LLC, Kyiv, Ukraine
🇧🇬UMHAT St. Ivan Rilski, Sofia, Bulgaria
🇺🇸Valerius Medical Group & Research Center, Los Alamitos, California, United States
A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT04883619
- Locations
- 🇺🇸
Omega Research Consultants, DeBary, Florida, United States
🇺🇸Valerius Medical Group & Research Center, Los Alamitos, California, United States
🇺🇸Respire Research, LLC, Palm Springs, California, United States
A Study of Nipocalimab in Healthy Male and Female Participants
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 89
- Registration Number
- NCT04848558
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.